Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue KC Prescription Drug List Policy Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue KCPolicy WF12304707-D 112023

    Prescription Drug List (PDL) — Pharmacy Utilization Management and Coverage Criteria

    Customize your policy alerts

    Sign up for Blue KC Policy WF12304707-D 112023 alerts

    Get alerted when Policy WF12304707-D 112023 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the Prescription Drug List (PDL), prior authorization, tiering, quantity limits, step therapy, specialty pharmacy use, and related pharmacy benefit processes for Blue KC members with a prescription drug benefit. Affects prescribers, pharmacists, and covered HMO, PPO, and EPO members.

    Policy Summary
    PayerBlue KC
    PolicyPrescription Drug List (PDL) — Pharmacy Utilization Management and Coverage Criteria
    Policy CodePolicy WF12304707-D 112023
    Change TypeNo material changes
    Effective DateJan 1, 2024
    Next Review Date
    Key ActionPrescribers must submit an electronic prior authorization request via the Blue KC provider portal when a drug is marked PA to obtain approval before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    QuarterlyPDL committee meeting frequency
    34-daySpecialty medication supply limit
    44,000+Network pharmacies nationwide
    816-395-2176Pharmacy Customer Service
    1Language/accessibility notice included

    Coverage and Benefit Rules

    General coverage criteria

    Covered when administrative and utilization management requirements listed in the PDL are satisfied:

    PDL listing or exception: Drug is listed on the Prescription Drug List (PDL) or has an approved exception/prior authorization from Blue KC.

    PDL status is determined by the Medical and Pharmacy Management Committee which reviews drugs quarterly.

    Prior authorization and step therapy: If the PDL annotates the drug with a prior authorization (PA) or step therapy (ST) requirement, the prescriber must obtain prior authorization or submit documentation of trial and failure/intolerance of required earlier‑line agents before coverage will be approved.

    Prescribers must submit electronic prior authorization requests via the Blue KC provider portal.

    Quantity limits: Coverage is subject to any quantity limits (QL) shown for the drug; dispensing in excess of the listed QL may be denied unless an approved exception is obtained.
    Policy Summary
    PayerBlue KC
    PolicyPrescription Drug List (PDL) — Pharmacy Utilization Management and Coverage Criteria
    Policy CodePolicy WF12304707-D 112023
    Change TypeNo material changes
    Effective DateJan 1, 2024
    Next Review Date
    Key ActionPrescribers must submit an electronic prior authorization request via the Blue KC provider portal when a drug is marked PA to obtain approval before dispensing.
    SourceLink
    On This Page
    Coverage and Benefit RulesFormulary Codes and IndicatorsPrior Authorization, Step Therapy, and DocumentationPolicy BackgroundKey Terms and AbbreviationsStep Therapy DetailsQuantity Limits (QL) by ProductSpecialty Pharmacy and Site-of-Care Requirements

    Quantity limits are part of the plan's utilization management rules.

    Specialty medication requirements: Specialty medications must be dispensed through the designated Specialty Pharmacy and are limited to a 34‑day supply.34-day supply

    Specialty Pharmacy provides clinical support, shipment and patient care coordination services.

    Some drug classes are not covered under the standard pharmacy benefit unless the member’s plan includes an additional rider/benefit. Examples called out in the formulary include fertility, birth control, impotency, and weight loss therapies — coverage for these classes requires the applicable rider to be active on the member’s policy.

    Syringes and needles are covered only by prescription and only for members using medications that require injection. Techlite/Arkray supplies are covered at $0 cost; other syringe/needle products are covered at a non-preferred brand copay. Requests for syringes/needles without a prescription or for non-injectable medication use are not eligible for coverage.

    Drugs listed with utilization management flags may be denied if plan requirements are not met. Specifically, a drug can be considered not covered when prior authorization (PA) is required but approval is not obtained, when the requested use is not an FDA‑approved or plan‑recognized indication, or when a lower‑cost or clinically preferred alternative (step therapy) applies and those alternatives have not been tried or documented as inappropriate. Providers should submit prior authorization requests and supporting documentation via the Blue KC provider processes to avoid claim denials.

    Formulary Codes and Indicators

    Restriction/Limit Codes shown in formulary Table of Contentsmixed
    PAPrior Authorization required
    STStep Therapy required
    QLQuantity Limit (specific quantities often given)
    MMedical necessity review / managed
    ACAAdditional clinical approval/code (as listed)
    inv-06: Selected quantity limits shown in formulary — examples of QL entries
    Example — acetaminophen-codeine oral solutionQL (136 ML per 1 day)
    Example — acetaminophen-codeine oral tablet 300-15 mgQL (13 EA per 1 day)
    Example — fentanyl transdermal patch (selected strengths)PA; QL (0.5 EA per 1 day)
    Example — butorphanol tartrate nasalQL (2.5 ML per 1 fill)
    Example — hydrocodone-acetaminophen oral solutionQL (98 ML per 1 day)
    Example — morphine sulfate oral solution 10 mg/5 mLQL (24.5 ML per 1 day)
    Most actionable — Specialty drugs supply limitSpecialty medications limited to a 34-day supply
    inv-07: Examples of Quantity Limits — specific sample QL values (terbinafine, rizatriptan, acyclovir external)
    Terbinafine hcl oralQL (84 supply per 180 days)
    Rizatriptan benzoate oral tablet dispersible 10 mgQL (0.4 EA per 1 day)
    Rizatriptan benzoate oral tablet dispersible 5 mgQL (0.6 EA per 1 day)
    Acyclovir external creamQL (0.17 GM per 1 day)
    Most actionable — Examples illustrate QL units and periodsConfirm dispense adheres to the listed QL (EA/ML/GM or supply per time period) to avoid denial

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior authorization requirement

    Prior Authorization Required: Blue KC requires prior authorization (PA) for many medications listed in this formulary. PA means the prescriber must obtain approval from Blue KC before the prescription will be covered; claims for drugs requiring PA may be denied if PA is not obtained. Prescribers should submit electronic prior authorization requests via the Blue KC provider portal (Providers > Forms > Prior Authorizations for Medications).

    • Definition: PA = Prior Authorization — the plan requires approval before filling or the drug may not be covered.
    • How to request: Submit an electronic prior authorization request via WWW.BlueKC.com > Providers > Forms > Prior Authorizations for Medications.
    Prior Authorization

    Prior authorization required for listed drugs

    Prior authorization is required for numerous listed drugs across the formulary. Examples of PA‑marked products include select analgesics, specialty agents, oncology, MS therapies, and various high‑cost or safety‑sensitive medications. Many entries in the Table of Contents show the restriction marker "PA" next to the drug name indicating PA is required prior to coverage.

    • Examples: fentanyl transdermal patches, hydrocodone ER formulations, several oncology oral agents (erlotinib, everolimus, imatinib), and specialty biologics (glatiramer, fingolimod) are PA‑marked in the formulary index.
    • Diabetes injectables and GLP‑1 agents (e.g., TRULICITY, VICTOZA, SYMLINPEN) show PA markers in the diabetes section.
    Prior Authorization

    Prior authorization and quantity limits

    Prior authorization and quantity limits: many drugs in the formulary require PA and/or have quantity limits (QL). When QL is present, the plan limits the amount dispensed per fill or per time period; when PA is present, authorization must be obtained even if quantity requested is within limits.

    • Common QL examples: multiple opioid preparations list QL (EA per day or ML per day) alongside PA where applicable.
    • Some specialty and oral oncology agents (e.g., erlotinib, everolimus) list PA plus a QL (e.g., 3 EA per 1 day or 1 EA per 1 day).
    • PA and QL must both be adhered to — requests exceeding QL or without PA may be denied.
    Denial Risk

    Prior authorization and restriction indicators

    Restriction indicators: the formulary uses utilization management markers to indicate required actions. Common markers include PA (Prior Authorization), QL (Quantity Limit), ST (Step Therapy), M (Maintenance), ACA (preventive/ACA), and OTC. Presence of these markers signals the need for additional provider action or documentation to secure coverage.

    • PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; M = Maintenance; ACA = Affordable Care Act preventive designation.
    • When a product is labeled with PA, ST, QL, or M, providers should expect potential denial or additional review unless requirements are met.
    Prior Authorization

    Prior authorization required for select agents

    Prior authorization required for select agents and specialty/high‑cost drugs: many specialty agents, MS therapies, oncology drugs, genetic/enzyme disorder treatments, and certain pulmonary or rare‑disease medications are PA‑designated. Examples in the index include glatiramer acetate, fingolimod, teriflunomide, miglustat, tolvaptan, lenalidomide, and several octreotide and leuprolide products.

    • MS therapies: dimethyl fumarate, glatiramer acetate, fingolimod, teriflunomide — PA and QL markers present.
    • Genetic/enzyme and specialty drugs: miglustat, tolvaptan, lenalidomide — PA marked.
    • Hormonal/injectable biologics: leuprolide acetate and octreotide products are PA‑designated.
    Prior Authorization

    Prior authorization required for PA‑marked medications

    Prior authorization required for PA‑marked medications across categories (e.g., analgesics, CNS, respiratory, metabolic bone disease, pulmonary fibrosis agents, diabetes injectables). Review the formulary index for specific PA markers adjacent to drug entries; when PA appears, secure authorization before dispensing.

    • Examples: certain extended‑release opioids, methylphenidate ER formulations, teriparatide, pirfenidone, and roflumilast are PA‑marked in the formulary.
    • Diabetes GLP‑1 and injectable devices (listed with PA in diabetes section) require PA for coverage.
    Note

    Prior authorization — not listed here / Not specified in this index

    Prior authorization — not listed here / Prior authorization not specified in this index: this section of the document is primarily an index/listing of drugs and restriction markers. Some index entries reference page numbers or are abbreviated and do not include full authorization criteria in the index itself. For full PA clinical criteria and documentation instructions, consult the corresponding policy pages or the Blue KC prior authorization forms on the provider site.

    • The index provides markers and page references only; it does not contain detailed PA clinical criteria or step‑by‑step documentation requirements.
    • If an index entry lacks a PA marker, it does not guarantee absence of authorization requirements — check the main policy text or online PA guidelines.
    Denial Risk

    Restriction codes indicate potential denial triggers

    Restriction codes indicate potential denial triggers: presence of PA, ST, QL, or M next to a drug name may trigger a claim denial or additional review if the required prior authorization, step‑therapy trial, or documentation is not provided. Providers must follow the indicated UM flag to avoid coverage denials.

    • Claims for PA‑flagged drugs will be denied if PA is not obtained.
    • ST markers require documented trial/failure of lower‑step therapies or an approved exception via PA.
    • Requests exceeding QL may be denied without appropriate justification.
    Documentation Required

    Documentation and quantity adherence

    Documentation and supporting clinical information: when PA, ST, QL, or other UM flags apply, providers should be prepared to submit supporting clinical documentation consistent with Blue KC policies (e.g., diagnosis, prior treatments, rationale for exception). Documentation supports review and can prevent delays or denials.

    • Provide clinical rationale, relevant trial history, diagnostic information, and dosing/quantity requested when submitting PA.
    • Specialty/MS agents and restricted drugs often require detailed documentation and may have QL or continuation criteria.
    Step Therapy

    Step therapy presence and requirements

    Step therapy presence and indicators: the formulary includes Step Therapy (ST) markers for select drug groups. ST requires trial of specified lower‑cost or preferred agents before coverage of a non‑preferred medication; if the prescriber believes the required step is inappropriate, a PA request with supporting documentation may be submitted.

    • ST examples: diclofenac potassium (ST), certain antidepressants/antimigraine combinations, methylphenidate ER and some gabapentin/pregabalin ER formulations (ST markers present).
    • If ST applies, submit documentation of trials and reasons for failure or intolerance of preferred agents when requesting an exception.

    Policy Background

    The Prescription Drug List (PDL) is developed and maintained by the Blue KC Medical and Pharmacy Management Committee, a local committee of physicians and pharmacists that reviews medications quarterly for safety, effectiveness, adverse events, comparative advantage, and cost. PDL status (tier placement, prior authorization, step therapy, and quantity limits) is assigned based on those reviews and post‑marketing information and informs coverage and utilization management decisions.

    Key Terms and Abbreviations

    inv-57: Brand vs Generic — definitions
    Definition — Brand-name drugA drug developed under patent protection; the patent prevents other manufacturers from copying the drug for a period of time
    Definition — Generic drugA product made after patent expiry with the same active ingredient and FDA approval; may differ in color, shape, or fillers and typically costs less
    Most actionable — Clinical implicationPrescribers and pharmacists may substitute FDA‑approved generics for brand products where appropriate to reduce cost
    inv-58: Generic equivalent vs Generic alternative — definitions
    Generic equivalentA medication that contains the same active ingredient and works the same way as the original brand-name drug
    Generic alternativeA generic medication that may not have the same active ingredient but works in the same way as another drug
    Most actionable — Formulary useUse generic equivalents when available; consider generic alternatives when equivalent is unavailable
    inv-59: Maintenance drug — definition
    Definition — Maintenance drugA medication used to treat a chronic condition (e.g., diabetes, hypertension) approved by the FDA for long-term use and identified via Medispan
    Most actionable — Dispensing practiceMaintenance drugs may be eligible for extended fills; check plan rules before dispensing multiple months' supply
    inv-60: Abbreviations — list (G, G-S, ACA, M, OTC, PA, etc.)
    GGeneric Drug
    G-SGeneric Specialty Drug
    ACAAffordable Care Act (preventive contraceptives may be covered at no cost)
    MMaintenance Drug
    OTCOver The Counter (non-prescription)
    PAPrior Authorization
    inv-61: Formulary restriction codes — PA, QL, M, ST definitions
    PAPrior Authorization — plan requires approval before drug will be covered (marked in formulary)
    QLQuantity Limit — maximum amount the plan will cover (units and time period shown alongside product)
    MManaged — indicates medical management review or restriction may apply
    STStep Therapy — requires trial of specified earlier-line agents before coverage of the listed product
    inv-62: PA — definition/marker
    PA markerSignifies that prior authorization may be required for coverage for the listed agent
    ContextWhen PA appears in Restrictions/Limits, providers must submit PA per Blue KC processes to obtain coverage
    inv-63: QL — definition/marker
    QL markerDenotes a Quantity Limit with specific maximum quantity and time period shown (e.g., EA/ML/GM per day or per 365 days)
    ContextDispensed quantity must adhere to the listed QL to avoid denial or need for exception/PA
    inv-64: ST — step therapy marker definition
    ST markerIndicates Step Therapy — a required trial of preferred/earlier-line therapies before coverage of the listed product
    Provider actionIf ST appears, prescriber must document trial/failure or request an exception via PA
    inv-65: ACA — Affordable Care Act marker context (contraceptives)
    ACA markerAppears on many contraceptive entries and links to Affordable Care Act preventive coverage categorization
    Coverage implicationACA‑marked preventive contraceptives may be covered at no cost per member benefits; verify member coverage details
    inv-66: Prior Authorization required — PA (short key)
    PA (short key)Prior Authorization required
    NoteListed as 'PA' in Restrictions/Limits column when applicable
    inv-67: Quantity Limit — QL (short key)
    QL (short key)Quantity Limit (maximum allowed per time period)
    NoteShown with specific units and period (EA/ML/GM per day or per 365 days)
    inv-68: Managed — M (medical management indicator)
    M (short key)Managed — medical management review or restriction applies
    Most actionableWhen 'M' appears, expect additional utilization review steps; confirm documentation requirements
    inv-69: Step Therapy required — ST (short key)
    ST (short key)Step Therapy required
    Provider actionIf 'ST' listed, prescriber must document prior trials or submit PA for exception
    inv-70: Index — indicates Index of Drugs
    Index markerIndicates Index of Drugs (cross-reference to drug pages)
    UseUse the Index to locate specific drug entries and associated restrictions/QL/PA markers

    Step Therapy Details

    AgentStep therapy requirement
    Agents marked 'ST' in the PDL (selected examples)
    Step therapy required per PDL — prescriber must try preferred/earlier‑line agents or submit prior authorization documenting failure/intolerance
    AgentStep therapy requirement
    Diclofenac potassium (migraine)
    Marked 'ST' in formulary; step therapy applies before coverage of the listed product
    Indomethacin (oral formulations; rectal suppository)
    Select indomethacin formulations listed with 'ST' restriction; step therapy required per PDL
    AgentStep therapy requirement
    Febuxostat
    Listed with 'ST' (and M) — step therapy requirement applies
    AgentStep therapy requirement
    Topiramate ER (extended release 24-hour)
    Entry shows Restrictions = ST for topiramate ER — step therapy applies
    Agent / product groupStep therapy requirement
    Select migraine and antigout agents (e.g., diclofenac potassium, febuxostat)
    Marked 'ST' in the formulary — step therapy required before coverage of the listed agent
    Select oncology or specialty agents (examples in table entries show ST on some antidiabetic and antiepileptic combination products)
    When 'ST' appears for a product, step edits must be satisfied or prior authorization submitted documenting why alternatives are inappropriate
    RuleNotes
    Step therapy applies to products labeled 'ST' in the PDL
    Prescribers must try required earlier‑line therapies or submit an electronic prior authorization request documenting failure/intolerance to obtain coverage
    Agent(s)Step therapy requirement
    Methylphenidate ER (selected ER formulations)
    Some methylphenidate ER products listed with 'ST' — step therapy applies (try preferred product first)
    Imiquimod external cream 3.75%; pimecrolimus
    Imiquimod 3.75% and pimecrolimus are listed with 'ST' (pimecrolimus also has QL) — step therapy applies
    ProductStep therapy requirement
    Insulin pen needles (various brands/sizes)
    Listed with 'ST' (and M; OTC for some) — step therapy markers present for specified pen needles
    Ophthalmic agents (selected: bepotastine, bromfenac etc.)
    Some ophthalmic products show 'ST' restriction markers per the formulary — step therapy edits may apply prior to coverage
    AgentStep therapy requirement
    Zileuton ER
    Listed with Restrictions = ST; M — step therapy applies to zileuton ER per formulary entry

    Quantity Limits (QL) by Product

    inv-80: Specialty medications — supply limit 34 (specialty supply limit)
    Specialty medications supply limit34-day supply (specialty medications are limited to a 34 day supply)
    Site of careMost specialty medications must be filled at the designated Specialty Pharmacy (Optum Specialty Pharmacy)
    ContactOptum Specialty Pharmacy Phone: 1-855-427-4682
    inv-81: Multiple specific formulary entries — various QL examples
    Example — ZUBSOLV (various strengths)QL entries vary by strength (e.g., 3 EA/day; 12 EA/day; 6 EA/day; 2 EA/day)
    Example — acetaminophen-codeine oral solution/tabletsMultiple QL values (e.g., 136 ML/day; 13 EA/day; 10 EA/day)
    Example — hydrocodone formulationsQL examples include 98 ML/day (solution) and 4 EA/day (tablets)
    Most actionable — Verify QL per formulationConfirm the specific strength/formulation QL listed for the product prior to fill to ensure compliance
    inv-82: ZUBSOLV sublingual tablets — QL varies by strength (examples provided)
    ZUBSOLV sublingual tablets — example strengthsQL varies by strength: 0.7-0.18 mg = QL (3 EA per 1 day); 1.4-0.36 mg = QL (12 EA per 1 day); 2.9-0.71 mg = QL (6 EA per 1 day); 8.6-2.1 mg = QL (2 EA per 1 day)
    NoteStrength-specific QL must be checked when dispensing ZUBSOLV
    inv-83: linezolid oral suspension — QL (32.2 ML per 1 day)
    Linezolid oral suspension (reconstituted)QL (32.2 ML per 1 day)
    Linezolid oral tabletQL (28 EA per 30 days)
    inv-84: dabigatran etexilate mesylate — QL (2 EA per 1 day)
    Dabigatran etexilate mesylateQL (2 EA per 1 day)
    ContextListed with 'M' and QL in anticoagulant section — adhere to QL when dispensing
    inv-85: bupropion ER/XR; duloxetine; venlafaxine ER — various QL entries
    Bupropion ER/XR (selected strengths)Restrictions include M; QL examples: 2 EA per day or 3 EA per 1 day depending on strength
    Duloxetine (selected)Restrictions include M; QL example: 2 EA per day
    Venlafaxine ER (selected)Restrictions include M; QL varies by product
    inv-86: Selected triptans — various QL per day or per 30 days
    Almotriptan malateQL (0.4 EA per 1 day)
    Rizatriptan dispersible 10 mgQL (0.4 EA per 1 day)
    Eletriptan hydrobromideQL (12 EA per 30 days)
    inv-87: terbinafine hcl oral — QL example (84)
    Terbinafine hcl oralQL (84 supply per 180 days)
    ContextAntifungal section lists terbinafine with 84 per 180 days — verify supply period when dispensing
    inv-88: almotriptan malate — QL (0.4)
    Almotriptan malateQL (0.4 EA per 1 day)
    ContextListed under Antimigraine Agents — adhere to per-day QL
    inv-89: oseltamivir phosphate capsules — QL examples by strength
    Oseltamivir phosphate capsules 30 mgQL (40 per 365 days)
    Oseltamivir phosphate capsules 45/75 mgQL (20 per 365 days)
    Most actionable — antiviral seasonal limitsObserve annual QL limits for oseltamivir formulations to ensure coverage
    inv-90: acyclovir external cream — QL (0.17)
    Acyclovir external creamQL (0.17 GM per 1 day)
    Acyclovir external ointmentQL (1 GM per 1 day)
    inv-91: lorazepam 0.5/1 mg — QL (3 EA per 1 day)
    Lorazepam 0.5 mg & 1 mg tabletsQL (3 EA per 1 day)
    Most actionable — lorazepam 0.5/1 mgAdhere to per-day QL when dispensing to avoid denial
    inv-92: lorazepam 2 mg — QL (5 EA per 1 day)
    Lorazepam 2 mg tabletQL (5 EA per 1 day)
    NoteHigher per-day QL applies to 2 mg strength vs 0.5/1 mg strengths
    inv-93: amphetamine sulfate — QL (6 EA per 1 day)
    Amphetamine sulfateQL (6 EA per 1 day)
    ContextListed under ADHD/CNS agents — adhere to per-day QL
    inv-94: methylphenidate solution 10 mg/mL — QL (30 ML per 1 day)
    Methylphenidate HCl oral solution 10 mg/mLQL (30 ML per 1 day)
    ContextLiquid formulation QL given in mL per day — confirm formulation when dispensing
    inv-95: dalfampridine ER — PA; QL (2 EA per 1 day)
    Dalfampridine ERPA; QL (2 EA per 1 day)
    ActionPA required plus adherence to QL — submit prior authorization per plan if needed
    inv-96: dimethyl fumarate starter pack — PA; QL (120 EA per 365 days)
    Dimethyl fumarate starter packPA; QL (120 EA per 365 days)
    ContextPA required for starter packs; annual QL applies
    inv-97: pregabalin capsules 100/150/200 mg — QL (3)
    Pregabalin capsules 100/150/200 mgQL (3 EA per 1 day)
    Most actionable — pregabalin 100/150/200 mgAdhere to 3 EA/day QL for these strengths
    inv-98: pregabalin 300 mg — QL (2)
    Pregabalin 300 mg capsuleQL (2 EA per 1 day)
    NoteLower QL for 300 mg strength compared with lower strengths
    inv-99: pregabalin oral solution — QL (30)
    Pregabalin oral solutionQL (30 ML per 1 day)
    ContextLiquid formulation QL given in mL per day
    inv-100: BYDUREON BCISE AUTOINJECTOR — QL example (0.15)
    BYDUREON BCISE AUTOINJECTORQL (0.15 ML per 1 day); Restrictions: PA; M
    Provider actionPA required for coverage; adhere to ML/day QL
    inv-101: BYETTA 10 MCG PEN — QL (0.08) and BYETTA 5 MCG PEN — QL (0.04)
    BYETTA 10 mcg penQL (0.08 ML per 1 day); Restrictions: PA; M
    BYETTA 5 mcg penQL (0.04 ML per 1 day); Restrictions: PA; M
    inv-102: MOUNJARO & OZEMPIC — QL examples
    MOUNJAROQL (0.08 ML per 1 day); Restrictions: PA
    OZEMPICQL (0.11 ML per 1 day); Restrictions: PA; M
    inv-103: RYBELSUS 3 MG — QL (60)
    RYBELSUS oral tablet 3 mgQL (60 EA per 365 days); Restrictions: PA; M
    RYBELSUS oral tablet 7/14 mgRestrictions: PA; M; QL (1 EA per ...)
    inv-104: TRULICITY & VICTOZA — QL examples
    TRULICITYQL (0.08 ML per 1 day); Restrictions: PA; M
    VICTOZAQL (0.3 ML per 1 day); Restrictions: PA; M
    inv-108: pimecrolimus — QL (2)
    Pimecrolimus (topical)QL (2 GM per day); Restrictions: ST
    ContextListed in dermatologic section — ST and per-day QL apply
    inv-109: calcipotriene-betameth diprop external ointment & suspension — QL (13.4 / 4)
    Calcipotriene-betamethasone dipropionate external ointmentQL (13.4 GM per 1 day)
    Calcipotriene-betamethasone dipropionate external suspensionQL (4 GM per 1 day)
    Most actionable — topical QL unitsObserve GM per day QLs for topical dermatologic agents when dispensing
    inv-111: CONTOUR test strips — QL (10)
    CONTOUR test stripsQL (10 EA per day); Restrictions: OTC
    ContextOTC test strips subject to daily QL — verify member benefits
    inv-112: tolvaptan & mifepristone — QL examples
    TolvaptanQL (2 EA per 1 day); Restrictions: PA
    MifepristoneQL (4 EA per 1 day)
    inv-114: glycopyrrolate tablets 1 mg/2 mg — QL (4)
    Glycopyrrolate oral tablet 1 mg/2 mgQL (4 EA per 1 day)
    ContextListed with M; ensure QL adherence when dispensing
    inv-115: Various QL examples (incassia, levonorgestrel, risedronate, bromfenac, loteprednol gel)
    Various contraceptives and ophthalmic/topical examplesExamples include QL (1 EA per ...), QL (0.15 EA per 1 day), QL (12 ML per 365 days), QL (20 GM per 365 days)
    ImplicationMultiple product-specific QLs appear across categories — always check the exact entry before dispensing
    inv-116: loteprednol etabonate ophthalmic gel — QL (20 GM per 365 days)
    Loteprednol etabonate ophthalmic gelQL (20 GM per 365 days)
    Most actionable — annual topical limitAdhere to 20 GM per year QL for loteprednol gel
    inv-117: tafluprost (pf) — QL (1 EA per 1 day)
    Tafluprost (PF)QL (1 EA per 1 day)
    ContextOphthalmic glaucoma agent — per-day QL applies
    inv-118: travoprost (b ak free) — QL (0.12 ML per 1 day)
    Travoprost (BAK-free)QL (0.12 ML per 1 day)
    ContextPer-day ML QL applies for travoprost — confirm bottle size vs QL

    Specialty Pharmacy and Site-of-Care Requirements

    Billing Rule

    Use designated Specialty Pharmacy for specialty meds

    Most specialty medications must be filled at the designated Specialty Pharmacy (Optum Specialty Pharmacy) and may be delivered to the physician's office or the patient's home; use the specialty pharmacy for dispensing specialty drugs.

    • Optum Specialty Pharmacy Phone: 1-855-427-4682
    • Specialty medications limited to a 34‑day supply